How Long Should the Lithium Augmentation Strategy be Maintained? A 1-Year Follow-up of a Placebo-Controlled Study in Unipolar Refractory Major Depression
Authors:
- Anne BerghöferAnne Berghöfer
- Andreas StröhleASAndreas Ströhle
- Dieter KunzDKDieter Kunz
- Mazda AdliMAMazda Adli
- Bruno Müller-OerlinghausenBMBruno Müller-Oerlinghausen
- Michael BauerMBMichael Bauer
- 1 August 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 22 (4) , 427-430
Abstract
There is compelling evidence from placebo-controlled studies that lithium augmentation is an effective strategy in the acute and continuation treatment of refractory unipolar major depression. Authors prospectively investigated the 1-year outcome of 22 subjects diagnosed with unipolar major depression who had participated in a 4-month placebo-controlled, double-blind continuation study of lithium augmentation without relapse. At the end of the double-blind phase, the blinded medication (lithium in 14 patients, placebo in 8 patients) was tapered off over a 1-week period, while the antidepressant was continued at the same dosage for another 4 weeks. Subsequently, the antidepressant was gradually discontinued over a 4-week period. Clinical status was assessed at regular follow-up visits. During the open 6-month follow-up period, seven subjects suffered an affective recurrence, five of whom had received lithium during the placebo-controlled, double-blind phase of the study. Study data suggest that active medication should be maintained for at least 1 year after successful lithium augmentation in patients with unipolar major depressive disorder.Keywords
This publication has 10 references indexed in Scilit:
- Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depressionJournal of Affective Disorders, 2001
- Double-Blind, Placebo-Controlled Trial of the Use of Lithium to Augment Antidepressant Medication in Continuation Treatment of Unipolar Major DepressionAmerican Journal of Psychiatry, 2000
- Lithium Augmentation in Treatment-Resistant Depression: Meta-Analysis of Placebo-Controlled StudiesJournal of Clinical Psychopharmacology, 1999
- Outcome in refractory depressionJournal of Affective Disorders, 1999
- Gradual Discontinuation of Lithium Augmentation in Elderly Patients With Unipolar DepressionJournal of Clinical Psychopharmacology, 1997
- A Double-Blind, Placebo-Controlled Study of Citalopram With and Without Lithium in the Treatment of Therapy-Resistant Depressive PatientsJournal of Clinical Psychopharmacology, 1996
- Placebo-Controlled Trial of Lithium Augmentation of Fluoxetine and LofepramineThe British Journal of Psychiatry, 1995
- A Placebo-Controlled Comparison of Lithium and Triiodothyronine Augmentation of Tricyclic Antidepressants in Unipolar Refractory DepressionArchives of General Psychiatry, 1993
- After lithium augmentation: a retrospective follow-up of patients with antidepressant-refractory depressionJournal of Affective Disorders, 1990
- Lithium Carbonate Addition in Tricyclic Antidepressant—Resistant Unipolar DepressionArchives of General Psychiatry, 1983